EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Inclusion Criteria:

• Male or female Asian patients 50 years of age or greater.

• Patients with primary or recurrent subfoveal CNV secondary to AMD, including thosewith predominantly classic, minimally classic or active occult lesions with no classiccomponent.

• Patients who have a BCVA score between 73 and 24 letters (approximately 20/40 to 20/320 Snellen equivalent), inclusively, in the study eye.

• Total area of CNV (including both classic and occult components) encompassed withinthe lesion must be >= 50% of the total lesion area

• Total lesion area must be <= 12 disc areas

Exclusion Criteria:

• Patients who have in the fellow eye a Snellen equivalent below 20/200

• Presence of angioid streaks, presumed ocular histoplasmosis syndrome, myopia (exceeding -8 diopters), or CNV secondary to causes other than AMD in the study eye

• Subfoveal fibrosis or atrophy in the study eye

• Total area of CNV (including both classic and occult components) encompassed withinthe lesion must be >= 50% of the total lesion area

• Total lesion area must be <= 12 disc areas

• Vitreous hemorrhage, retinal tear or history of rhegmatogenous retinal detachment ormacular hole (Stage 3 or 4) in the study eye.

• Active, or history of, ocular inflammation or infection in the study eye within thelast 30 days prior to screening.

• Uncontrolled glaucoma in the study eye

• Treatment in the study eye with verteporfin, external-beam radiation therapy,subfoveal focal laser photocoagulation, vitrectomy, submacular surgery, ortranspupillary thermotherapy within 30 days prior to screening

• Previous treatment with anti-angiogenic drugs (pegaptanib, ranibizumab, bevacizumab,anecortave acetate, corticosteroids, protein kinase C inhibitors, squalamine, siRNA,VEGF-Trap etc.) for neovascular AMD in the study eye. Treatment of the fellow eye ispermitted if administered > 30 days before screening.

• History of intraocular surgery in the study eye including pars plana vitrectomy,except for uncomplicated cataract surgery more than 60 days prior to screening

• History of YAG laser posterior capsulotomy in the study eye within 30 days prior toscreening